MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Metrics, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics, Inc. Enhances the Bioavailability of Poorly Water Soluble Drugs - Benefits of new proprietary SUBA technology include improved and consistent drug absorption, reducing patient variability and, potentially, side effects - MetricsInc.com
Metrics, Inc. Enhances the Bioavailability of Poorly Water Soluble Drugs

 

NewswireToday - /newswire/ - Raleigh, NC, United States, 2013/04/23 - Benefits of new proprietary SUBA technology include improved and consistent drug absorption, reducing patient variability and, potentially, side effects - MetricsInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Metrics, Inc. is offering a new proprietary technology (SUBA™) that enhances the bioavailability of poorly water-soluble drugs.

A solid dispersion is formed between the drug and specific pharmaceutically acceptable polymers. The dispersions, in powder form, are delivered to the body via hard gelatin capsules or tablets. Once in the small intestine, the drug-polymer combination changes form, presenting the drug in a way that is much more rapidly absorbed through the intestinal wall compared to standard crystalline forms of the drug.

“The small intestine absorbs certain active pharmaceutical ingredients including those that are poorly water soluble more readily than does the stomach,” said Dr. Brad Gold, vice president of pharmaceutical development. “SUBA technology takes advantage of the body’s natural digestive processes to deliver a poorly water-soluble active ingredient to the place where it can do the most good.”

Potential benefits of SUBA technology include fewer side effects for patients and reduced intra- and inter-patient variability, Gold added,“which is especially important when pharmaceutical companies are studying new drug therapies in clinical trials.”

Metrics Inc. (metricsinc.com) is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. The addition of SUBA technology to Metrics’ portfolio of formulation and manufacturing capabilities is the result of its recent acquisition by Mayne Pharma Group Limited.

Mayne Pharma has successfully applied SUBA technology to improve the bioavailability of the poorly soluble and highly variable anti-fungal drug itraconazole, and has recently received regulatory approval to market this significantly improved formulation of itraconazole (brand name Lozanoc®) in a number of European markets.

Together, Metrics and Mayne offer an impressive proprietary portfolio of advanced drug delivery technologies for controlled release, bioavailability enhancement and taste masking. By collaborating with partners, the companies can develop and distribute novel prescription and over-the-counter products that offer advantages over existing products and meet unmet medical needs. Applied appropriately, these technologies can deliver therapeutic or convenience benefits to patients, including a reduced dosing frequency, increased compliance, improved side effect profile and a more constant therapeutic effect.

Metrics’ areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical trial manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Headquartered in Greenville, N.C., Metrics proudly operates as a subsidiary of Mayne Pharma.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Metrics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Metrics, Inc. Enhances the Bioavailability of Poorly Water Soluble Drugs

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Karen Stinneford - Sinclair-Co.com for Metrics 
919-833-9102 kstinneford[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Metrics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Metrics, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)